PHF-Tau蛋白正子造影劑之發展與應用

Current Status of PET Radiotracers for PHF-Tau Pathology in Neurodegeneration

10.6332/ANMMI.3001.007

黃雅瑤(Ya-Yao Huang)；曾凱元(Kai-Yuan Tzen)；顏若芳(Ruoh-Fang Yen)

阿茲海默氏症 ； 神經退化性疾病 ； 正子造影 ； PHF-tau蛋白 ； AD ； neurodegeneration ； PET ； PHF-tau

核子醫學暨分子影像雜誌

30卷1期（2017 / 03 / 01）

38 - 53

繁體中文

PHF-tau蛋白已知與許多神經退化性疾病有關，例如阿茲海默氏症(Alzheimer's disease, AD)。因此，PHF-tau蛋白之正子造影劑已被認為可用以早期準確地診斷AD，並應用於相關治療藥物的開發。目前於國內外，發展一具潛力PHF-tau蛋白之正子造影劑已是一重要研究方向，且已有初步的結果。本文將針對部分已應用在臨床造影的PHF-tau蛋白正子造影劑做一簡單的介紹，包括其於AD以外神經退化性疾病的臨床應用。

The pathway leading to hyperphosphorylated, insoluble and filamentous tau protein (PHF-tau) is at the centre of many human neurodegenerative diseases such as Alzheimer's disease (AD). The development of selective PET radiotracers targeting PHF-tau is critical for early and accurate diagnosis, as well as the successful development of disease-modifying therapies. For AD, selective PET radiotracers for β-amyloid are already available, and potential PHF-tau tracers are emerging as new-generation biomarkers. This article summarizes the development scenario of PET PHF-tau radiotracer and their potential role for diagnosing and treating AD, as well as future clinical applications in regards to differential diagnoses of tau-related non-AD neurodegenerative diseases.